About

Hemostemix is a autologous (patient's own) stem cell company in the clinical trial stage that provides angiogenic cell precursors to generate new vascularization for patients suffering from ischemic conditions who have no other options available. Our patented platform VasCell (ACP-01) uses the patient's own blood products to rebuild blood flow when everything else fails. Our technology is NOT FDA approved, but is available in certain locations through compassionate care legislation and wherever local law allows. Our clinical trials results point to positive outcomes. Visit our website for more: https://hemostemix.com